

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

**UVESCREEN1: A randomised feasibility study of imaging-based uveitis screening for children with juvenile idiopathic arthritis- Study Protocol**

Short title: UVESCREEN1 Protocol

Authors: Sonali Dave<sup>1</sup>, Jugnoo Rahi<sup>1,2,3,4,5</sup>, Harry Petrushkin<sup>2,4,6</sup>, Ilaria Testi<sup>2,4,6</sup>, Dipesh E Patel<sup>1,3,4,6</sup>, Ameenat Lola Solebo<sup>1,2,3,6</sup>

**Affiliations:**

1. Population, Policy and Practice Programme, UCL GOS Institute of Child Health, London, UK
2. Great Ormond Street Hospital for Children NHS Trust, London UK
3. National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital and UCL GOS ICH, London, UK
4. National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK
5. Ulverscroft Vision Research Group, London, UK
6. Moorfields Eye Hospital NHS Trust, London, UK

**Corresponding author:** Ameenat Lola Solebo 0000-0002-8933-586

Postal address: UCL GOS Institute of Child Health, 30 Guilford Street, London, WC1N 1EH, UK. Email address: [a.solebo@ucl.ac.uk](mailto:a.solebo@ucl.ac.uk)

## 25 **Abstract**

26 Children with Juvenile Idiopathic Arthritis (JIA) are at a currently unpredictable risk of a  
27 blinding, often asymptomatic, co-existent eye disorder, anterior uveitis which requires prompt  
28 treatment. The unpredictability of this insidious disorder commits children with JIA to three-  
29 monthly expert clinical examination in specialist eye centres often located far from their homes.  
30 Optical coherence tomography of the ocular anterior segment (AS-OCT) has been shown to be  
31 an acceptable, repeatable and sensitive modality for uveitis detection, but is not standard care.  
32 This feasibility randomised controlled trial (RCT) aims to inform a future full-scale RCT  
33 comparing current routine practice (expert slit lamp examination, SLE) to AS-OCT for the  
34 surveillance of uveitis in children at risk.

35 Eighty children aged between 2 and 12 years old and diagnosed with JIA within the preceding  
36 year will be included. Participants with an existing diagnosis of uveitis, other ocular co-  
37 morbidities or those unable to complete examinations or provide informed assent will be  
38 excluded. Participants will be randomised to SLE (control) or AS-OCT (intervention)  
39 examination at a frequency consistent with the current national programme for childhood  
40 uveitis surveillance. Children in the intervention arm will also have standard examination at 6  
41 and 12 months after study entrance. Outcomes of interest will be feasibility (recruitment and  
42 attrition rates), clinical metrics (proportion diagnosed with uveitis or other ocular disorders at  
43 12 months after study entrance), quality of life outcomes (PedsQL), and resource use.  
44 Additionally, comparative analysis of AS-OCT versus SLE ('gold standard' reference testing)  
45 findings at 6 and 12 months for those in the intervention arm will provide the proof-of-concept  
46 data necessary to develop and undertake a larger scale trial.

47 Trial registration: This trial has been registered with [clinicaltrials.gov](https://clinicaltrials.gov) (NCT05984758).

## 48 **Summary**

49 Anterior uveitis is a rare form of eye disease that is commonly associated with Juvenile  
50 Idiopathic Arthritis (JIA). Childhood uveitis is potentially blinding, so children with JIA must  
51 travel to a specialist centre every two to three months for an eye examination to pick up signs  
52 of uveitis. This feasibility study will compare routine Slit Lamp Examination (SLE) with  
53 imaging-based surveillance using Optical Coherence Tomography of the Anterior Segment  
54 (AS-OCT) to support the design of a future study. Eighty children between the ages of two  
55 and twelve years old who have been diagnosed with JIA in the past year will be invited to  
56 take part. Children will be randomised into one of two arms (SLE or AS-OCT) and will have  
57 their routine uveitis screening appointments over one year using either of the screening  
58 modalities. This study will provide the proof-of-concept data necessary to develop and  
59 undertake a larger scale trial.

## 60 **Introduction**

61 Childhood uveitis is a rare but significant chronic eye condition [1]. Whilst childhood onset  
62 disease accounts for approximately 1% of cases seen in adult uveitis clinics [2, 3], it accounts  
63 for 10% of cases of uveitis related sight impairment amongst adults [4, 5]. This over-  
64 representation is compounded by the frequent presence of multisystem disorders amongst those  
65 with childhood onset uveitis [6]. A key example is Juvenile Idiopathic Arthritis (JIA), the most  
66 common childhood inflammatory arthropathy [7]. Uveitis affecting the front section of the eye  
67 (anterior uveitis) the most common extra-articular manifestation of JIA [8] Childhood anterior  
68 uveitis can be asymptomatic, or occur in children too young to report symptoms, so children  
69 with JIA undergo regular eye surveillance examinations every few months [9].

70

71 The strongest predictor of poor outcomes in childhood onset uveitis is the presence of  
72 established ocular structural complications at presentation i.e. delayed diagnosis [10]. The  
73 worsening international workforce shortfall in paediatric ophthalmology is an obstacle to  
74 timely diagnosis for this population [11]. Imaging-based disease surveillance, which could be  
75 undertaken in settings across primary to tertiary care [12], would address this shortfall in  
76 capacity, providing specialist level care (potentially closer to the child's home) to facilitate  
77 timely diagnosis and reduce the burden of uveitis related visual impairment amongst children  
78 and the adults they become.

79

80 Optical Coherence Tomography (OCT) machines have been widely adopted in secondary care  
81 and primary care settings (including high street opticians), providing high resolution images of  
82 eye structures [13]. OCT of the anterior segment (AS-OCT) to detect inflammatory cells in the  
83 eye, the hallmark of anterior uveitis, has been shown to be repeatable and highly sensitive for  
84 childhood disease [14]. Work has also been undertaken to understand the normative findings

85 in healthy children [15]. The implementation of this potentially transformational innovation  
86 needs robust evidence on safety and effectiveness.

87 We aim to begin to provide the necessary high-level evidence, through a feasibility randomised  
88 controlled trial of AS-OCT versus routine clinical examination for the detection of uveitis in  
89 children at risk. This proof-of-concept study will compare imaging-based surveillance to the  
90 current approach of clinical examination (slit lamp examination-based surveillance) in the  
91 detection of uveitis in children with juvenile idiopathic arthritis. The proposed study will  
92 provide the data needed to develop eligibility criteria, recruitment and retention approaches, to  
93 determine the key outcome metrics and study sample size necessary to demonstrate non-  
94 inferiority, and to inform the selection of the resource use measures needed to determine cost-  
95 effectiveness.

96

## 97 **Materials and Methods**

98 The proposed study has been designed in line with the SPIRIT (Standard Protocol Items:  
99 Recommendations for Interventional Trials) guidelines [16].

100

### 101 *Study design*

102 This study will be a two-arm, parallel group, single site feasibility randomised controlled trial  
103 (RCT) comparing slit lamp examination-based (SLE, routine care) with AS-OCT based  
104 detection of active anterior chamber inflammation over 52 weeks in children undergoing  
105 surveillance examinations for juvenile idiopathic associated uveitis. Study participants will be  
106 children newly diagnosed (within the preceding 12 months) with JIA. The primary outcomes  
107 will be study feasibility metrics (i.e. recruitment and attrition rates). Proof of concept  
108 analyses will also be undertaken, with comparison of AS-OCT assessment to ‘gold standard’  
109 clinical examination at 6 and 12 months.

110

111 ***Setting***

112 This will be a single site study, undertaken within a tertiary/quaternary healthcare setting:

113 Great Ormond Street Hospital (GOSH), England, UK. Participants will be identified and

114 recruited on attendance to routine outpatient appointments.

115

116 ***Participants***

117 Eligibility criteria comprise:

- 118
- 119 • New diagnosis (within preceding 12 months) of JIA
  - 120 • Eligible for uveitis surveillance in line with national guidance (table 1) [9]
  - 121 • Aged between 2 and 12 years

122 Exclusion criteria comprise:

- 123 • Visual impairment or any ocular co-morbidities that would negatively impact on  
124 best corrected acuity
- 125 • Developmental/learning difficulties that preclude concordance with  
126 examination/informed assent

First eye examination within 6 weeks of referral Two monthly intervals from onset of arthritis for 6 months Then 3-4 monthly eye examinations for time outlined below:	
Age at onset	Length of surveillance
Less than 3 years <sup>a</sup>	8 years
3-4 years <sup>a</sup>	6 years
5-8 years <sup>a</sup>	3 years
9-10 years <sup>a</sup>	1 year
Less than 6 years <sup>b</sup>	5 years
6-9 years <sup>b</sup>	2 years
Any age <sup>c</sup>	5 years

127 **Table 1-** Guidelines for screening for uveitis in JIA by the Royal College of  
128 Ophthalmologists and the British Society for Paediatric and Adolescent Rheumatology  
129 (BSPAR).

130 <sup>a</sup>- For oligoarticular JIA, Psoriatic arthritis onset and Enthesitis related arthritis (ERA)

131 <sup>b</sup>- For polyarticular, ANA+ JIA onset < 10 years

132 <sup>c</sup>- For polyarticular, ANA- JIA, onset <7 years

133

#### 134 ***Study intervention - AS-OCT***

135 Children randomised to the intervention arm will undergo AS-OCT imaging to detect anterior  
136 chamber inflammation. The AS-OCT images will be acquired using the Optovue RTVue OCT  
137 (8 cross-sectional scans) and the Heidelberg Spectralis OCT2 machines (anterior segment cube  
138 scan). Images will undergo manual analysis by a trained clinician to identify the presence of  
139 inflammatory cells within the anterior chamber. A later semi-automated re-analysis of acquired  
140 images will be undertaken within one week of the examination using published protocols [12,  
141 14]. Full details of image acquisition and analysis processes are available in supplemental  
142 document 1 (S1).

143

144 Imaging will be undertaken at a frequency consistent with line with national guidance (table 1)  
145 [9]. This comprises 6 study visits in total (at Month 2 following the first visit to establish  
146 eligibility, Month 4, Month 6, Month 9, and Month 12- see table 1 for further details). The full  
147 participant schedule of assessments is shown in figure 1, with specific details of the study  
148 procedures shown in figure 2.

149

150 Exit from the study will occur either at visit 7 (for participants with a new diagnosis of JIA  
151 within 6 months of entrance to study), at visit 6 (for participants whose JIA was diagnosed  
152 within 6 to 12 months of study entrance, figure 1), or at any visit where uveitis has been  
153 diagnosed. A diagnosis of uveitis will be made clinically, using slit lamp examination. Any  
154 child within the intervention arm in whom a ‘disease positive’ AS-OCT is acquired (i.e. more  
155 than 1 hyper-reflective particle in any cross-sectional scan) will undergo a confirmatory slit  
156 lamp examination. Confirmation of uveitis will lead to a child exiting the study.  
157



158 **Figure 1-** SPIRIT schedule of assessments.

159 <sup>a</sup> Visits for those within 6 months of diagnosis: newly diagnosed: Day 1, Week 8, Week 16,  
160 Week 28, Week 40, last visit Week 52

161 Visits for those entering study outside the 6-month window: Day 1, Week 13, Week 26, Week  
162 39, Week 52

163 <sup>b</sup> Concomitant use of a. immunosuppression or immunomodulation (and dose); any eye or  
164 visual symptoms since last visit; any other parental concerns

165 <sup>c</sup> Measured with age-appropriate method: Cardiff cards, Thomson Kays or Thomson  
166 LogMAR in each eye separately

167 <sup>d</sup> Heidelberg Spectralis OCT2 and Optovue RTVue anterior segment cube and single line  
168 scans

169 <sup>e</sup> A diagnosis of new onset uveitis at any visit results in exit from the trial  
170

171 **Figure 2-** Details about the specific procedures during the intervention and control arm. \*-

172 See supplemental document 2 (S2) for specific visual acuity screening protocol

173

#### 174 **Study outcome measures**

175 The main outcomes of interest are the study feasibility metrics, specifically

176 - The proportion of patients within the service who meet the eligibility criteria, and reasons for  
177 exclusion

178 - The proportion of eligible patients recruited

179 - The proportion of patients who withdraw due to loss of consent or are lost to follow-up

180 - Statistical parameters (point estimates and range / variance) of the clinical and patient centred  
181 outcome measures

182 The primary clinical outcome measured (as a surrogate endpoint) will be:

183 - Agreement, for participants in the intervention arm, of AS-OCT findings with routine clinical  
184 examination, analysed at 6 months and 12 months milestones

185 Other clinical outcomes of interest will be:

186 - New diagnosis of uveitis

187 - New diagnosis of other visual/ocular problems

188 We shall be evaluating patient centred outcomes, specifically

189 - Health related quality of life (PedsQL child self-report, at 12 months and change from  
190 baseline to 12 months)

191 We shall also be evaluating resource use across the feasibility study to support the design of  
192 cost-effectiveness analyses in the larger scale study.

193

194 Adverse and serious adverse events (AE/SAE) will be recorded for both the intervention and  
195 routine care arms. These events comprise (1) Development of anterior chamber  
196 inflammation; (2) development of non-sight threatening sequelae of ocular inflammation  
197 during the study period; (3) progression or disease flare of JIA; (4) development of treatment  
198 related adverse events. AE/SAE occurring in the intervention arms will be used as criteria to  
199 determine progression to a full RCT. Specifically, the progression criteria will be defined  
200 using a ‘traffic-light’ system (green – criteria met, amber – minor changes needed, red –  
201 significant changes needed).

202 Recruitment

203 - Green – >4 recruits/month

204 - Yellow – 2-4 recruits/month

205 - Red – <2 recruits/month

206 Adverse events (incidence of sight threatening complications in imaging-based surveillance  
207 group)

208 - Green / Yellow – No cases

209 - Red – >1 case

210 Adherence to surveillance programme

211 - Green – >75%

212 - Yellow – 30-75%

213 - Red – <30%

214

215 ***Sample size***

216 As a feasibility study, there is no formal power calculation based on clinical non-inferiority  
217 for a diagnostic intervention [17]. To ‘quantify’ and assess the concept that imaging-based  
218 surveillance is not inferior to clinical slit-lamp examination in the detection of active anterior  
219 uveitis in children at risk, the starting point will be that that SLE findings (assumed to be  
220 abnormal in 100% of children with an active anterior uveitis) and AS-OCT findings will  
221 concord in at least 95%.

222

223 ***Recruitment***

224 Following identification through medical record review and confirmation of eligibility at  
225 routine clinical review, participants will be approached postally, using posted participant  
226 information sheets, or by telephone, 1-2 weeks prior to the next planned outpatient attendance.  
227 Informed consent will be sought by a member of the research team within a week of being  
228 given the study documentation. Assent will also be sought from participating children where  
229 appropriate [18, 19] (see supplemental material 3 (S3) for the consent and assent forms to be  
230 used in the study). To minimise participant attrition, after entering the trial families will receive  
231 telephone calls a few days ahead of each visit to support attendance, and financial support for  
232 travel costs.

233

234 ***Randomisation and allocation***

235 Coordinated registration and allocation of participant trial numbers will be used. Participants  
236 will be allocated using computer-generated permuted block randomisation into one of two arms  
237 (1:1, block size= 4) stratified by age (8 and under, over 8). This will be undertaken centrally  
238 by the coordinating trial team using Sealed envelope ([www.sealedenvelope.com](http://www.sealedenvelope.com)). Allocation

239 will not be concealed, and participants cannot be masked to their allocation to routine (slit lamp  
240 examination) or imaging-based surveillance (AS-OCT) examinations.

241

### 242 ***Data collection and processing***

243 Data will be entered into electronic data collection forms (DCFs) using the REDCap platform,  
244 with collection undertaken during study visits by research associates or clinicians and reviewed  
245 for completeness by an investigator. Alongside the data collection forms, optical coherence  
246 tomography (OCT) images will be collected from participants.

247 To limit data missingness, the following approaches will be used:

248 - Validation rules within the REDCap form (i.e. form submission will not be permitted if data  
249 entry points have not been completed)

250 - Incoming data review monthly by the study team and screening committee to identify  
251 missingness, and any patterns of / reasons for missingness within the study dataset

252 - Exclusion from outcomes analysis of participants lacking a full dataset for more than two  
253 consecutive study visits

254 Patient data will not be transferred to any party not identified in this protocol and will not to be  
255 processed and/or transferred other than in accordance with the patients' consent. Direct access  
256 to the data will be granted to authorised representatives from the Sponsor, host institution and  
257 the regulatory authorities to permit study-related monitoring, audits and inspections. This trial  
258 will collect personal data (e.g. participant names), including special category personal data (e.g.  
259 participant medical information) and this will be handled in accordance with all applicable data  
260 protection legislation. Data (including special category) will only be collected, used and stored  
261 if necessary for the trial. The database and randomisation system will be designed to protect  
262 patient information in line with the GDPR. All documents will be stored securely and only  
263 accessible by study staff and authorised personnel.

264

265 ***Analysis***

266 Proportions will be reported as point estimates with 95% confidence intervals. Levels of  
267 missing data will be explored with respect to certain baseline characteristics, e.g. age and  
268 measures of disease severity to assess biases. All harms or unintended effects in each group  
269 will be reported. Effect size (of ‘discrimination’ of disease) and variability in outcomes will be  
270 estimated with 95% confidence intervals to inform the sample size calculations for a full-scale  
271 trial. Initial trial success will be defined as: recruitment rates of >4 recruits/month, or  
272 generation of information on barriers to recruitment; adverse event (incidence of new sight  
273 threatening complications in imaging-based surveillance group) rate of 0; adherence to  
274 surveillance programme of >75% or understanding of barriers to adherence. We will seek to  
275 identify potential cost drivers to inform the collection of the data for cost-effectiveness analyses  
276 within a future definitive study.

277

278 ***Data monitoring***

279 This study will be overseen by a study steering committee (SC). The UVESCREEN1 SC will  
280 consist of the Chief Investigator, trial staff, and invited members who represent clinical, clinical  
281 researcher, and patient stakeholders. The SC will review interim analysis of recruitment  
282 figures, adverse and serious adverse events, trial conduct and any substantial amendments to  
283 the protocol. The committee will meet 2-3 times a year.

284

285 The Chief Investigator will be responsible for the day-to-day monitoring and management of  
286 the study. The Chief Investigator will ensure there is adequate monitoring of activities  
287 conducted by the study team. This will include adherence to the protocol, procedures for  
288 consenting and adequate data quality. The Chief Investigator will inform the Sponsor if there

289 are concerns that have arisen from monitoring activities, and/or if there are problems with  
290 oversight/monitoring procedures. Any changes to the protocol including changes to the  
291 eligibility criteria, outcomes or analysis will be reported to the study team, sponsor and REC  
292 by the chief investigator.

293

#### 294 ***Ethics considerations and declarations***

295 This study had received ethics approval from Yorkshire & The Humber - Leeds West  
296 Research Ethics Committee (REF 23/YH/0237, accepted protocol version V2, date  
297 18/10/2023). The study will be carried out in accordance with the Declaration of Helsinki and  
298 all participants will provide written or electronic informed consent.

299

#### 300 ***Patient and Public Involvement (PPI)***

301 The development of this study has been supported by a patient expert group, the Childhood  
302 Uveitis Study steering group [20, 21]. This proposal is also driven by the priorities identified  
303 by stakeholders (patients and professional groups) who participated in the 2013 James Lind  
304 Alliance Priority Setting Partnership (JLA PSP) [22].

305

#### 306 ***Dissemination***

307 We estimate participant recruitment to be completed by April 2026 with data collection to be  
308 completed by October 2026. Results will be analysed and disseminated approximately six  
309 months later. Findings will be disseminated through journal articles and presentations at both  
310 academic and medical conferences. Contributors to (i) the design, conduct, data analysis and  
311 interpretation, (ii) writing, (iii) manuscript approval and (iv) accountability for the integrity of  
312 the work will, depending on their contribution and journal requirements, will be included by  
313 name at the manuscript head. The Uniform Requirements for Manuscripts Submitted to

314 Biomedical Journals (<http://www.icmje.org/>) will be respected in manuscripts generated by this  
315 study. At the end of the trial, after the primary results have been published, the anonymised  
316 individual participant data (IPD) and associated documentation (e.g. protocol, statistical  
317 analysis plan, annotated blank CRF) will be prepared in order to be shared with external  
318 researchers.

319

## 320 **Discussion**

321 This feasibility, proof-of-concept RCT will compare imaging-based surveillance to routine  
322 clinical examination in the detection of uveitis in children at risk, providing the information  
323 necessary for the design of a future study. This information will comprise feasibility data  
324 needed to finalise eligibility criteria, recruitment and retention approaches, and data to  
325 determine the key outcome metrics and study sample size necessary to demonstrate non-  
326 inferiority, and the resource use measures needed to determine cost-effectiveness. Study  
327 findings are intended to inform the development of a full scale RCT to determine whether  
328 imaging-based uveitis surveillance is non-inferior to routine surveillance with regards to  
329 detection of childhood anterior uveitis in those at risk. Qualitative interviews will also be  
330 completed with selected participants (n=10) to establish acceptability amongst participants and  
331 families and to aid implementation into practice. Longer term impact will be evaluated through  
332 the planned full-scale trial.

333

334 Attempts to ensure timely diagnosis of childhood uveitis are frustrated by the worsening  
335 shortfall in the number of appropriately trained specialists. In some areas of the United  
336 Kingdom, children with juvenile idiopathic arthritis are not accessing ophthalmic care within  
337 the recommended time window [23]. Across the UK, there is a workforce crisis in paediatric  
338 ophthalmology [11]. This crisis is replicated globally [24]. The wide community adoption of

339 OCT provides a platform for the use of AS-OCT to address some of these challenges.  
340 Specifically, the use of AS-OCT detection of active anterior uveitis would release patients from  
341 the need to attend hospital eye specialist clinics, as imaging could be undertaken in community  
342 eye health centres. The findings from this proposed research project would support the future  
343 implementation of hospital and community based anterior segment imaging-based uveitis  
344 surveillance for populations at particular risk but would also be the foundation of future  
345 imaging-based surveillance at whole population level. They also provide a chance to put  
346 children first, with childhood disease driving the science and implementation, and supporting  
347 later wider adoption for adult uveitis. Adult disease is common relative to childhood uveitis  
348 (incidence 17-52.4 per 100,000 versus incidence 2-20 per 100,000) [25, 26], is a major cause  
349 of working age blindness [27] and is the most common cause of attendance to acute eye care  
350 services [28].

351 There are limitations inherent in the design of the proposed study. Firstly, due to the study  
352 design, it is not possible for the participants and research team to be masked to the arm to which  
353 participants have been allocated, and this may introduce the risk of researcher bias. Equally,  
354 due to the nature of the intervention, it is not possible for study participants to be masked to  
355 their study arm, which also potentially risks information bias in patient reported outcomes. A  
356 pragmatic design, in which each child undertook both standard and interventional examination,  
357 with randomisation of which examination would be used for assessment, may be the approach  
358 taken for future studies, informed by the findings of this feasibility trial. Secondly, recruitment  
359 will only take place at a single site, potentially limiting the generalisability of the data.  
360 Additionally, this site is a highly specialised care setting, with participants poorly  
361 representative of the ‘average’ patient. Again, as this is a feasibility study, informing a future  
362 larger scale study, there will be exploration and description of the representativeness of the  
363 recruited patient sample, and reflection of how that compares to what is known about the



364 characterises of the wider population of children at risk. Participants in this study will be  
365 reimbursed for their travel and will consent to regular phone calls to support attendance. As  
366 this deviates from routine care, it can be argued that this reduces the generalisability of the  
367 study. However, the findings from this study will provide a baseline for best achievable attrition  
368 rate to as comparison for the full RCT, where generalisability will be considered again.

369

370 In conclusion, this study will provide vital information about the feasibility of conducting a  
371 larger scale trial on SLE versus AS-OCT uveitis screening examinations for children with JIA.  
372 The data collected in this study will also provide valuable insight into the practical  
373 considerations needed before implementing this into a larger scale RCT.

374

## 375 **Authors' contributions**

376 Conceptualization: ALS

377 Writing- Original draft and Preparation: ALS and SD

378 Writing – Review & Editing: ALS, SD, JR, HP, DEP, IT

379 Methodology: ALS

380 Visualization: ALS and SD

381

## 382 **Data Availability**

383 No datasets were generated or analysed during the current study.

384

385 **Acknowledgements** We thank the Childhood Uveitis (patient expert) Studies steering group  
386 for their support.

387



## 389 **References**

- 390 1. Smith JA, Mackensen F, Sen HN, Leigh JF, Watkins AS, Pyatetsky D, et al.  
391 Epidemiology and course of disease in childhood uveitis. *Ophthalmology*. 2009;116(8):  
392 1544-51. doi:10.1016/j.ophtha.2009.05.002.
- 393 2. Hart CT, Zhu EY, Crock C, Rogers SL, Lim LL. Epidemiology of uveitis in urban  
394 Australia. *Clin Exp Ophthalmol*. 2019;47(6): 733-40. doi: 10.1111/ceo.13517.
- 395 3. Jones NP. The Manchester Uveitis Clinic: the first 3000 patients--epidemiology and  
396 casemix. *Ocul Immunol Inflamm*. 2015;23(2): 118-26. doi: 10.3109/09273948.2013.855799.
- 397 4. Bodaghi B, Cassoux N, Wechsler B, Hannouche D, Fardeau C, Papo T, et al. Chronic  
398 severe uveitis: etiology and visual outcome in 927 patients from a single center. *Medicine*.  
399 2001;80(4): 263-70. doi: 10.1097/00005792-200107000-00005.
- 400 5. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and  
401 frequency of blindness in patients with intraocular inflammatory disease. *Br J Ophthalmol*.  
402 1996;80(4): 332-6. doi: 10.1136/bjo.80.4.332.
- 403 6. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic  
404 arthritis: functional outcome. *Rheumatology*. 2002;41(12): 1428-35.  
405 doi:10.1093/rheumatology/41.12.1428.
- 406 7. Costello A, Rasooly I, Weiss P. Rheum for Improvement? Delayed Diagnosis of  
407 Juvenile Idiopathic Arthritis: A Narrative Review. *Arthritis Care Res (Hoboken)*. 2024. doi:  
408 10.1002/acr.25438.
- 409 8. Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. *Clin Immunol*.  
410 2020;211. doi: 10.1016/j.clim.2019.108322.
- 411 9. Guidelines for screening for uveitis in juvenile idiopathic arthritis (JIA) [Internet].  
412 The Royal College of Ophthalmologists. 2006 [cited 2024 Dec 10]. Available from:  
413 [https://www.rcophth.ac.uk/resources-listing/guidelines-for-screening-for-uveitis-in-juvenile-](https://www.rcophth.ac.uk/resources-listing/guidelines-for-screening-for-uveitis-in-juvenile-idiopathic-arthritis-jia/)  
414 [idiopathic-arthritis-jia/](https://www.rcophth.ac.uk/resources-listing/guidelines-for-screening-for-uveitis-in-juvenile-idiopathic-arthritis-jia/).
- 415 10. Gregory AC, 2nd, Kempen JH, Daniel E, Kaçmaz RO, Foster CS, Jabs DA, et al. Risk  
416 factors for loss of visual acuity among patients with uveitis associated with juvenile  
417 idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study.  
418 *Ophthalmology*. 2013;120(1): 186-92. doi: 10.1016/j.ophtha.2012.07.052.
- 419 11. New RCOphth Workforce Census illustrates the severe shortage of eye doctors in the  
420 UK [Internet]. The Royal College of Ophthalmologists. 2019 [cited 2024 Dec 10]. Available

- 421 from: [https://www.rcophth.ac.uk/news-views/new-rcophth-workforce-census-illustrates-the-](https://www.rcophth.ac.uk/news-views/new-rcophth-workforce-census-illustrates-the-severe-shortage-of-eye-doctors-in-the-uk/)  
422 [severe-shortage-of-eye-doctors-in-the-uk/](https://www.rcophth.ac.uk/news-views/new-rcophth-workforce-census-illustrates-the-severe-shortage-of-eye-doctors-in-the-uk/)
- 423 12. Akbarali S, Rahi JS, Dick AD, Parkash K, Etherton K, Edelsten C, et al. Imaging-  
424 Based Uveitis Surveillance in Juvenile Idiopathic Arthritis: Feasibility, Acceptability, and  
425 Diagnostic Performance. *Arthritis Rheumatol.* 2021;73(2): 330-5. doi: 10.1002/art.41530.
- 426 13. Liu X, Solebo AL, Faes L, Beese S, Braithwaite T, Round ME, et al. Instrument-  
427 based Tests for Measuring Anterior Chamber Cells in Uveitis: A Systematic Review. *Ocul*  
428 *Immunol Inflamm.* 2020;28(6): 898-907. doi: 10.1080/09273948.2019.1640883.
- 429 14. Etherton K, Rahi JS, Petrushkin H, Dick AD, Akbarali S, Pattani R, et al. Quantitative  
430 and qualitative assessment of anterior segment optical coherence tomography capture of  
431 disease state in childhood anterior uveitis. *Br J Ophthalmol.* 2023;107(7): 966-72. doi:  
432 10.1136/bjophthalmol-2021-320448.
- 433 15. Solebo AL, Bellchambers A, Kellett S, Rahi JS, Dick AD. Establishing the Normative  
434 Data Set Necessary for Imaging-Based Childhood Uveitis Surveillance: A Cross-Sectional  
435 Study. *Invest Ophthalmol Vis Sci.* 2024;65(1):9. doi:10.1167/iovs.65.1.9.
- 436 16. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al.  
437 SPIRIT 2013 statement: defining standard protocol items for clinical trials. *Ann Intern Med.*  
438 2013;158(5): 200-7. doi: 10.7326/0003-4819-158-3-201302050-00583.
- 439 17. Totton N, Lin J, Julious S, Chowdhury M, Brand A. A review of sample sizes for UK  
440 pilot and feasibility studies on the ISRCTN registry from 2013 to 2020. *Pilot Feasibility Stud.*  
441 2023;9(1):188. doi: 10.1186/s40814-023-01416-w
- 442 18. Oulton K, Gibson F, Sell D, Williams A, Pratt L, Wray J. Assent for children's  
443 participation in research: why it matters and making it meaningful. *Child Care Health Dev.*  
444 2016;42(4): 588-97. doi: 10.1111/cch.12344.
- 445 19. Tait AR, Geisser ME. Development of a consensus operational definition of child  
446 assent for research. *BMC Med Ethics.* 2017;18(1):41. doi: 10.1186/s12910-017-0199-4.
- 447 20. Kellett S, Rahi JS, Dick AD, Knowles R, Tadić V, Solebo AL. UNICORNS: Uveitis  
448 in childhood prospective national cohort study protocol. *F1000Res.* 2020;9:1196. doi:  
449 10.12688/f1000research.26689.2.
- 450 21. Solebo AL, Kellett S. Inclusive study design to better serve the needs of children and  
451 young people with rheumatological conditions. *Lancet Rheumatol.* 2024;6(11):e746. doi:  
452 10.1016/S2665-9913(24)00271-6.
- 453 22. Rowe F, Wormald R, Cable R, Acton M, Bonstein K, Bowen M, et al. The Sight Loss  
454 and Vision Priority Setting Partnership (SLV-PSP): overview and results of the research

- 455 prioritisation survey process. *BMJ Open*. 2014;4(7):e004905. doi: 10.1136/bmjopen-2014-  
456 004905.
- 457 23. Angeles-Han ST, Srivastava SK. Screening, Monitoring, and Treating Children With  
458 Juvenile Idiopathic Arthritis-associated Uveitis: Visualizing Better Outcomes. *J Rheumatol*.  
459 2023;50(3): 300-3. doi: 10.3899/jrheum.221092.
- 460 24. Berkowitz ST, Finn AP, Parikh R, Kuriyan AE, Patel S. Ophthalmology Workforce  
461 Projections in the United States, 2020 to 2035. *Ophthalmology*. 2024;131(2): 133-9. doi:  
462 10.1016/j.ophtha.2023.09.018.
- 463 25. Al-Ani HH, Sims JL, Tomkins-Netzer O, Lightman S, Niederer RL. Vision loss in  
464 anterior uveitis. *Br J Ophthalmol*. 2020;104(12): 1652-7. doi: 10.1136/bjophthalmol-2019-  
465 315551.
- 466 26. Kolomeyer AM, Crane ES, Tu Y, Liu D, Chu DS. Adult patients with uveitis  
467 associated with juvenile idiopathic arthritis: a retrospective review. *Can J Ophthalmol*.  
468 2017;52(5): 458-62. doi: 10.1016/j.jcjo.2017.01.011.
- 469 27. Tomkins-Netzer O, Talat L, Bar A, Lula A, Taylor SR, Joshi L, Lightman S. Long-  
470 term clinical outcome and causes of vision loss in patients with uveitis. *Ophthalmology*.  
471 2014;121(12): 2387-92. doi: 10.1016/j.ophtha.2014.07.007.
- 472 28. Edelsten C, Reddy MA, Stanford MR, Graham EM. Visual loss associated with  
473 pediatric uveitis in english primary and referral centers. *Am J Ophthalmol*. 2003;135(5): 676-  
474 80. doi: 10.1016/s0002-9394(02)02148-7.

475

476

## 477 **Supporting documents**

478 Supplemental material 1: Imaging acquisition protocol

479 Supplemental material 2: Specific visual acuity screening protocol

480 Supplemental material 3: Consent and Assent forms

481

	Screening	Baseline	Intervention phase					Final visit
Visit No:	1	2	3	4	5	6	7	8 or 9 <sup>e</sup>
Week (new diagnosis) <sup>a</sup>		-	Week 0	Week 8	Week 16	Week 28	Week 40	Week 52
Week (recent diagnosis) <sup>a</sup>		-	Week 0	Week 13	Week 26	Week 39	-	Week 52
Window of flexibility for timing of visits:			+/- 7 days	+/- 7 days	+/- 7 days	+/- 7 days	+/- 7 days	+/- 7 days
Informed Consent	X							
Medical History	X	X						
Eligibility confirmation	X	X	X					
Randomisation		X						
History <sup>b</sup>		X	X	X	X	X	X	X
Visual acuity <sup>c</sup>		X	X	X	X	X	X	X
Slit lamp examination (control group)		X	X	X	X	X	X	X
Slit lamp examination (intervention group, new diagnosis)		X				X		X
Slit lamp examination (intervention group, recent diagnosis)		X			X			X
OCT acquisition (intervention group) <sup>d</sup>			X	X	X	X	X	X
Adverse Events review			X	X	X	X	X	X
Concomitant Medication review		X	X	X	X	X	X	X
PedsQL child self-report			X					X
Visual analogue scoring of examination procedures			X					X

Figure 1

## Procedures at each visit for control group (i.e. standard care)

**History: concomitant use of immunosuppression or immunomodulation (and dose)**

**History: any eye or visual symptoms since last visit**

**History: any other parental concerns**

Visual acuity – measured with age-appropriate methods\*: Thompson Kays, or Thompson LogMAR, in each eye separately, with correction if needed

Slit lamp assessment of anterior chamber using SUN, scores for AC cells and AC flare

Other findings on eye examination (normal or abnormal with details)

## Specific intervention procedures at each visit for intervention group (italicised where interventions divert from standard care)

**History: concomitant use of immunosuppression or immunomodulation (and dose)**

**History: any eye or visual symptoms since last visit**

**History: any other parental concerns**

Visual acuity measured with age-appropriate methods\*: Thompson Kays, or Thompson LogMAR, in each eye separately, with correction if needed

### **Anterior segment OCT acquisition:**

*Heidelberg Spectralis OCT2 anterior segment cube scan*

*Heidelberg Spectralis OCT2 anterior segment single line scan*

*Optovue RTVue OCT anterior segment cube scan*

*Optovue RTVue OCT anterior segment single line scan*

Figure 2